1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Radiopharmaceutical CDMO Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Radiopharmaceutical CDMO Market, by Application
8.1.1. Diagnostic Radiopharmaceuticals
8.1.1.1. Market Revenue and Forecast
8.1.2. Therapeutic Radiopharmaceuticals
8.1.2.1. Market Revenue and Forecast
9.1. Radiopharmaceutical CDMO Market, by Radioisotope Type
9.1.1. Fluorine-18
9.1.1.1. Market Revenue and Forecast
9.1.2. Technetium-99m
9.1.2.1. Market Revenue and Forecast
9.1.3. Gallium-68
9.1.3.1. Market Revenue and Forecast
9.1.4. Lutetium-177
9.1.4.1. Market Revenue and Forecast
9.1.5. Actinium-225
9.1.5.1. Market Revenue and Forecast
10.1. Radiopharmaceutical CDMO Market, by Service Type
10.1.1. Contract Manufacturing
10.1.1.1. Market Revenue and Forecast
10.1.2. Contract Development
10.1.2.1. Market Revenue and Forecast
10.1.3. Analytical & Quality Control Services
10.1.3.1. Market Revenue and Forecast
10.1.4. Packaging, Labeling & Logistics
10.1.4.1. Market Revenue and Forecast
11.1. Radiopharmaceutical CDMO Market, by Therapeutic Area
11.1.1. Oncology
11.1.1.1. Market Revenue and Forecast
11.1.2. Neurology
11.1.2.1. Market Revenue and Forecast
11.1.3. Cardiology
11.1.3.1. Market Revenue and Forecast
11.1.4. Others (Nephrology, Inflammation, Rare Diseases)
11.1.4.1. Market Revenue and Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Application
12.1.2. Market Revenue and Forecast, by Radioisotope Type
12.1.3. Market Revenue and Forecast, by Service Type
12.1.4. Market Revenue and Forecast, by Therapeutic Area
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Application
12.1.5.2. Market Revenue and Forecast, by Radioisotope Type
12.1.5.3. Market Revenue and Forecast, by Service Type
12.1.5.4. Market Revenue and Forecast, by Therapeutic Area
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Application
12.1.6.2. Market Revenue and Forecast, by Radioisotope Type
12.1.6.3. Market Revenue and Forecast, by Service Type
12.1.6.4. Market Revenue and Forecast, by Therapeutic Area
12.2. Europe
12.2.1. Market Revenue and Forecast, by Application
12.2.2. Market Revenue and Forecast, by Radioisotope Type
12.2.3. Market Revenue and Forecast, by Service Type
12.2.4. Market Revenue and Forecast, by Therapeutic Area
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Application
12.2.5.2. Market Revenue and Forecast, by Radioisotope Type
12.2.5.3. Market Revenue and Forecast, by Service Type
12.2.5.4. Market Revenue and Forecast, by Therapeutic Area
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Application
12.2.6.2. Market Revenue and Forecast, by Radioisotope Type
12.2.6.3. Market Revenue and Forecast, by Service Type
12.2.6.4. Market Revenue and Forecast, by Therapeutic Area
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Application
12.2.7.2. Market Revenue and Forecast, by Radioisotope Type
12.2.7.3. Market Revenue and Forecast, by Service Type
12.2.7.4. Market Revenue and Forecast, by Therapeutic Area
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Application
12.2.8.2. Market Revenue and Forecast, by Radioisotope Type
12.2.8.3. Market Revenue and Forecast, by Service Type
12.2.8.4. Market Revenue and Forecast, by Therapeutic Area
12.3. APAC
12.3.1. Market Revenue and Forecast, by Application
12.3.2. Market Revenue and Forecast, by Radioisotope Type
12.3.3. Market Revenue and Forecast, by Service Type
12.3.4. Market Revenue and Forecast, by Therapeutic Area
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Application
12.3.5.2. Market Revenue and Forecast, by Radioisotope Type
12.3.5.3. Market Revenue and Forecast, by Service Type
12.3.5.4. Market Revenue and Forecast, by Therapeutic Area
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Application
12.3.6.2. Market Revenue and Forecast, by Radioisotope Type
12.3.6.3. Market Revenue and Forecast, by Service Type
12.3.6.4. Market Revenue and Forecast, by Therapeutic Area
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Application
12.3.7.2. Market Revenue and Forecast, by Radioisotope Type
12.3.7.3. Market Revenue and Forecast, by Service Type
12.3.7.4. Market Revenue and Forecast, by Therapeutic Area
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Application
12.3.8.2. Market Revenue and Forecast, by Radioisotope Type
12.3.8.3. Market Revenue and Forecast, by Service Type
12.3.8.4. Market Revenue and Forecast, by Therapeutic Area
12.4. MEA
12.4.1. Market Revenue and Forecast, by Application
12.4.2. Market Revenue and Forecast, by Radioisotope Type
12.4.3. Market Revenue and Forecast, by Service Type
12.4.4. Market Revenue and Forecast, by Therapeutic Area
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Application
12.4.5.2. Market Revenue and Forecast, by Radioisotope Type
12.4.5.3. Market Revenue and Forecast, by Service Type
12.4.5.4. Market Revenue and Forecast, by Therapeutic Area
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Application
12.4.6.2. Market Revenue and Forecast, by Radioisotope Type
12.4.6.3. Market Revenue and Forecast, by Service Type
12.4.6.4. Market Revenue and Forecast, by Therapeutic Area
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Application
12.4.7.2. Market Revenue and Forecast, by Radioisotope Type
12.4.7.3. Market Revenue and Forecast, by Service Type
12.4.7.4. Market Revenue and Forecast, by Therapeutic Area
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Application
12.4.8.2. Market Revenue and Forecast, by Radioisotope Type
12.4.8.3. Market Revenue and Forecast, by Service Type
12.4.8.4. Market Revenue and Forecast, by Therapeutic Area
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Application
12.5.2. Market Revenue and Forecast, by Radioisotope Type
12.5.3. Market Revenue and Forecast, by Service Type
12.5.4. Market Revenue and Forecast, by Therapeutic Area
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Application
12.5.5.2. Market Revenue and Forecast, by Radioisotope Type
12.5.5.3. Market Revenue and Forecast, by Service Type
12.5.5.4. Market Revenue and Forecast, by Therapeutic Area
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Application
12.5.6.2. Market Revenue and Forecast, by Radioisotope Type
12.5.6.3. Market Revenue and Forecast, by Service Type
12.5.6.4. Market Revenue and Forecast, by Therapeutic Area
13.1. Curium Pharma
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. Eckert & Ziegler
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. ITM Isotope Technologies Munich
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. NorthStar Medical Radioisotopes
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. Cardinal Health
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. SOFIE Biosciences
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. PharmaLogic Holdings
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. SpectronRx
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
13.9. Monrol (Eczacıbaşı-Monrol)
13.9.1. Company Overview
13.9.2. Product Offerings
13.9.3. Financial Performance
13.9.4. Recent Initiatives
13.10. SHINE Technologies
13.10.1. Company Overview
13.10.2. Product Offerings
13.10.3. Financial Performance
13.10.4. Recent Initiatives
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
15.1. About Us
15.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
